Bisoprolol is a beta-1 adrenergic blocking agent used to prevent myocardial infarction and heart failure and to treat mild to moderate hypertension.

Brand Names
Generic Name
DrugBank Accession Number

Bisoprolol is a cardioselective β1-adrenergic blocking agent used to treat high blood pressure.4,17 It is considered a potent drug with a long-half life that can be used once daily to reduce the need for multiple doses of antihypertensive drugs.4 Bisoprolol is generally well tolerated, likely due to its β1-adrenergic receptor selectivity and is a useful alternative to non-selective β-blocker drugs in the treatment of hypertension such as Carvedilol and Labetalol. It may be used alone or in combination with other drugs to manage hypertension17 and can be useful in patients with chronic obstructive pulmonary disease (COPD) due to its receptor selectivity.13

Small Molecule
Average: 325.443
Monoisotopic: 325.225308485
Chemical Formula
  • (+-)-1-((alpha-(2-Isopropoxyethoxy)-p-tolyl)oxy)-3-(isopropylamino)-2-propanol
  • (RS)-1-(4-(2-Isopropoxyethoxymethyl)phenoxy)-3-(isopropylamino)-2-propanol
  • Bisoprolol
  • Bisoprololum
External IDs
  • CL 297,939
  • CL 297939
  • EMD 33 512
  • EMD 33512



Bisoprolol is indicated for the treatment of mild to moderate hypertension.17 It may be used off-label to treat heart failure, atrial fibrillation, and angina pectoris.1,2

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Associated Conditions
Indication TypeIndicationCombined Product DetailsApproval LevelAge GroupPatient CharacteristicsDose Form
Management ofAtrial fibrillation••• •••••
Prophylaxis ofCardiac event••• •••••
Management ofHeart failure••• •••••
Used in combination to manageHigh blood pressure (hypertension)•••••••••••••••••••••••
Management ofHigh blood pressure (hypertension)•••••••••••••••••••••••
Contraindications & Blackbox Warnings
Prevent Adverse Drug Events Today
Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events with our Clinical API
Learn more

Bisoprolol decreases heart rate (chronotropy), decreases contractility (inotropy), and reduces blood pressure.15,17 The results of various clinical studies indicate that bisoprolol reduces cardiovascular mortality and all-cause mortality in patients with heart failure and decreased cardiac ejection fraction (EF).3,8

Mechanism of action

Though the mechanism of action of bisoprolol has not been fully elucidated in hypertension, it is thought that therapeutic effects are achieved through the antagonism of β-1adrenoceptors to result in lower cardiac output. Bisoprolol is a competitive, cardioselective β1-adrenergic antagonist. When β1-receptors (located mainly in the heart)15 are activated by adrenergic neurotransmitters such as epinephrine, both the blood pressure and heart rate increase, leading to greater cardiovascular work, increasing the demand for oxygen. Bisoprolol reduces cardiac workload by decreasing contractility and the need for oxygen through competitive inhibition of β1-adrenergic receptors.7,15

Bisoprolol is also thought to reduce the output of renin in the kidneys, which normally increases blood pressure. Additionally, some central nervous system effects of bisoprolol may include diminishing sympathetic nervous system output from the brain, decreasing blood pressure and heart rate.17

ABeta-1 adrenergic receptor
NBeta-2 adrenergic receptor

Bisoprolol is well absorbed in the gastrointestinal tract.18 The bioavailability of bisoprolol is about 90% due to the minimal first-pass effects.1 Absorption is unaffected by food intake.1

Peak plasma concentrations of bisoprolol are attained within 2-4 hours and steady-state concentrations are achieved within 5 days of administration.17 In a pharmacokinetic study, the mean peak concentration of bisoprolol was 52 micrograms/L.6 Cmax at steady state concentrations of bisoprolol is 64±21 ng/ml administered at 10 mg daily.18

The area under the curve (AUC) following oral administration of 10mg bisoprolol ranged from 597 to 661 ug/L x h. Following intravenous administration of the same dosage, the AUC was 672 ug/L x h.1

Volume of distribution

The volume of distribution of bisoprolol is 3.5 L/kg.18 The mean volume of distribution was found to be 230 L/kg in heart failure patients, which was similar to the volume of distribution in healthy patients.10 Bisoprolol is known to cross the placenta.16

Protein binding

Binding to serum proteins is approximately 30%.9,18


Approximately 50% of the bisoprolol dose is eliminated by non-renal pathways. Bisoprolol is metabolized through oxidative metabolic pathways with no subsequent conjugation. Bisoprolol metabolites are polar and, therefore, really eliminated. Major metabolites found in plasma and urine are inactive. Bisoprolol is mainly metabolized by CYP3A4 (95%), whereas CYP2D6 plays a minor role. The CYP3A4-mediated metabolism of bisoprolol appears to be non-stereoselective.14,17,23

Route of elimination

Bisoprolol is eliminated equally by both renal and hepatic pathways. About 50% of an oral dose is excreted unchanged in the urine with the remainder of the dose excreted as inactive bisoprolol metabolites. Under 2% of the ingested dose is found to be excreted in the feces.17,18


A pharmacokinetic study in 12 healthy individuals determined the mean plasma half-life of bisoprolol to be 10-12 hours.4 Another study comprised of healthy patients determined the elimination half-life to be approximately 10 hours.6 Renal impairment increased the half-life to 18.5 hours.6


Total body clearance in healthy patients was determined to be 14.2 L/h. In patients with renal impairment, clearance was reduced to 7.8 L/h. Hepatic dysfunction also reduced the clearance of bisoprolol.6

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!
See the data
Improve decision support & research outcomes with our structured adverse effects data.
See a data sample

LD50 information Oral LD50 of bisoprolol in the mouse was 730 mg/kg.21

Overdose information

Signs of a β-blocker overdose include cardiovascular symptoms such as hypotension, congestive heart failure, and bradycardia. Other symptoms such as bronchospasm, and hypoglycemia may occur. If an overdose occurs with bisoprolol, supportive treatment should be initiated. Glucagon has been shown to be beneficial in bradycardia and hypotension associated with beta-blocker overdosage.11 Hypoglycemia may be managed by administering IV glucose.17 Monitor the patient and administer atropine in cases of bradycardia, pressors and fluids in the case of hypotension, and conventional heart failure therapy if heart failure occurs. If heart block occurs, the patient must be closely monitored and isoproterenol infusion or transvenous cardiac pacemaker insertion should take place.17 For the management of overdose-related bronchospasm, administer bronchodilators with or without IV aminophylline. Limited research suggests that bisoprolol fumarate is not removed adequately by hemodialysis sessions.12,17

Bisoprolol Action PathwayDrug action
Pharmacogenomic Effects/ADRs
Not Available


Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
AbacavirBisoprolol may decrease the excretion rate of Abacavir which could result in a higher serum level.
AbaloparatideThe risk or severity of adverse effects can be increased when Bisoprolol is combined with Abaloparatide.
AbametapirThe serum concentration of Bisoprolol can be increased when it is combined with Abametapir.
AbemaciclibThe serum concentration of Abemaciclib can be increased when it is combined with Bisoprolol.
AbrocitinibThe serum concentration of Bisoprolol can be increased when it is combined with Abrocitinib.
Food Interactions
  • Take with or without food. The absorption is unaffected by food.


Drug product information from 10+ global regions
Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.
Access now
Access drug product information from over 10 global regions.
Access now
Product Ingredients
IngredientUNIICASInChI Key
Bisoprolol fumarateUR59KN573L104344-23-2VMDFASMUILANOL-WXXKFALUSA-N
Product Images
International/Other Brands
Bisocor / Cardicor (Bayer) / Concor (Merck) / Concore (Merck) / Detensiel (Merck Santé) / Emconcor (Merck) / Emcor (Merck) / Euradal (Lacer) / Isoten (Meda) / Monocor (Biovail Pharmaceuticals) / Soprol (Helsinn)
Brand Name Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing EndRegionImage
BisoprololTablet5 mgOralSanis Health Inc2012-10-01Not applicableCanada flag
BisoprololTablet10 mgOralSorres Pharma Inc2009-02-262014-06-20Canada flag
BisoprololTablet10 mgOralSivem Pharmaceuticals Ulc2012-06-122020-07-21Canada flag
BisoprololTablet5 mgOralSorres Pharma Inc2009-02-262014-06-20Canada flag
BisoprololTablet10 mgOralSanis Health Inc2012-10-01Not applicableCanada flag
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing EndRegionImage
Ag-bisoprololTablet10 mgOralAngita Pharma Inc.2022-03-18Not applicableCanada flag
Ag-bisoprololTablet5 mgOralAngita Pharma Inc.2022-03-18Not applicableCanada flag
Apo-bisoprololTablet10 mgOralApotex Corporation2004-08-10Not applicableCanada flag
Apo-bisoprololTablet5 mgOralApotex Corporation2004-08-10Not applicableCanada flag
Ava-bisoprololTablet10 mgOralAvanstra Inc2011-08-222014-08-21Canada flag
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing EndRegionImage
BIRAMLO 10MG/10MGBisoprolol fumarate (10 mg/1) + Amlodipine besylate (10 mg/1)TabletOral2018-10-01Not applicableGermany flag
BIRAMLO 10MG/10MGBisoprolol fumarate (10 mg/1) + Amlodipine besylate (10 mg/1)TabletOral2018-10-01Not applicableGermany flag
BIRAMLO 10MG/10MGBisoprolol fumarate (10 mg/1) + Amlodipine besylate (10 mg/1)TabletOral2018-10-01Not applicableGermany flag
BIRAMLO 10MG/5MGBisoprolol fumarate (10 mg/1) + Amlodipine besylate (5 mg/1)TabletOral2018-10-01Not applicableGermany flag
BIRAMLO 10MG/5MGBisoprolol fumarate (10 mg/1) + Amlodipine besylate (5 mg/1)TabletOral2018-10-01Not applicableGermany flag
Unapproved/Other Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing EndRegionImage
CONCOR 10 MG 30 LAK TABLETBisoprolol fumarate (10 mg)TabletOralDAİİCHİ SANKYO İLAÇ TİC. LTD. ŞTİ.2013-01-29Not applicableTurkey flag
CONCOR 5 MG 30 LAK TABLETBisoprolol fumarate (5 mg)TabletOralDAİİCHİ SANKYO İLAÇ TİC. LTD. ŞTİ.2013-01-29Not applicableTurkey flag


ATC Codes
C07FX04 — Bisoprolol and acetylsalicylic acidC07BB07 — Bisoprolol and thiazidesC07AB07 — BisoprololC09BX05 — Ramipril and bisoprololC09BX02 — Perindopril and bisoprololC09BX04 — Perindopril, bisoprolol and amlodipineC09BX06 — Perindopril, bisoprolol, amlodipine and indapamideC07FB07 — Bisoprolol and amlodipine
Drug Categories
Chemical TaxonomyProvided by Classyfire
This compound belongs to the class of organic compounds known as benzylethers. These are aromatic ethers with the general formula ROCR' (R = alkyl, aryl; R'=benzene).
Organic compounds
Super Class
Benzene and substituted derivatives
Sub Class
Direct Parent
Alternative Parents
Phenoxy compounds / Phenol ethers / Alkyl aryl ethers / Secondary alcohols / 1,2-aminoalcohols / Dialkylamines / Dialkyl ethers / Organopnictogen compounds / Hydrocarbon derivatives
1,2-aminoalcohol / Alcohol / Alkyl aryl ether / Amine / Aromatic homomonocyclic compound / Benzylether / Dialkyl ether / Ether / Hydrocarbon derivative / Organic nitrogen compound
Molecular Framework
Aromatic homomonocyclic compounds
External Descriptors
secondary alcohol, secondary amine (CHEBI:3127)
Affected organisms
  • Humans and other mammals

Chemical Identifiers

CAS number
InChI Key


Synthesis Reference

Yoshihiro Iwao, Katsuyuki Ookubo, Katsuhiro Okada, Kunihiro Minami, Shuichiro Yuasa, "Adhesive Pharmaceutical Preparation Containing Bisoprolol." U.S. Patent US20090169604, issued July 02, 2009.

General References
  1. Lancaster SG, Sorkin EM: Bisoprolol. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in hypertension and angina pectoris. Drugs. 1988 Sep;36(3):256-85. doi: 10.2165/00003495-198836030-00002. [Article]
  2. Ishiguro H, Ikeda T, Abe A, Tsukada T, Mera H, Nakamura K, Yusu S, Yoshino H: Antiarrhythmic effect of bisoprolol, a highly selective beta1-blocker, in patients with paroxysmal atrial fibrillation. Int Heart J. 2008 May;49(3):281-93. [Article]
  3. Metra M, Nodari S, Bordonali T, Milani P, Lombardi C, Bugatti S, Fontanella B, Verzura G, Danesi R, Dei Cas L: Bisoprolol in the treatment of chronic heart failure: from pathophysiology to clinical pharmacology and trial results. Ther Clin Risk Manag. 2007 Aug;3(4):569-78. [Article]
  4. Leopold G, Ungethum W, Pabst J, Simane Z, Buhring KU, Wiemann H: Pharmacodynamic profile of bisoprolol, a new beta 1-selective adrenoceptor antagonist. Br J Clin Pharmacol. 1986 Sep;22(3):293-300. doi: 10.1111/j.1365-2125.1986.tb02890.x. [Article]
  5. Nuttall SL, Routledge HC, Kendall MJ: A comparison of the beta1-selectivity of three beta1-selective beta-blockers. J Clin Pharm Ther. 2003 Jun;28(3):179-86. [Article]
  6. Kirch W, Rose I, Demers HG, Leopold G, Pabst J, Ohnhaus EE: Pharmacokinetics of bisoprolol during repeated oral administration to healthy volunteers and patients with kidney or liver disease. Clin Pharmacokinet. 1987 Aug;13(2):110-7. doi: 10.2165/00003088-198713020-00003. [Article]
  7. Chatterjee SS: The cardioselective and hypotensive effects of bisoprolol in hypertensive asthmatics. J Cardiovasc Pharmacol. 1986;8 Suppl 11:S74-7. [Article]
  8. Dezsi CA, Szentes V: The Real Role of beta-Blockers in Daily Cardiovascular Therapy. Am J Cardiovasc Drugs. 2017 Oct;17(5):361-373. doi: 10.1007/s40256-017-0221-8. [Article]
  9. Leopold G: Balanced pharmacokinetics and metabolism of bisoprolol. J Cardiovasc Pharmacol. 1986;8 Suppl 11:S16-20. [Article]
  10. Cvan Trobec K, Grabnar I, Kerec Kos M, Vovk T, Trontelj J, Anker SD, Rosano G, Lainscak M: Bisoprolol pharmacokinetics and body composition in patients with chronic heart failure: a longitudinal study. Eur J Clin Pharmacol. 2016 Jul;72(7):813-22. doi: 10.1007/s00228-016-2041-1. Epub 2016 Mar 21. [Article]
  11. Peterson CD, Leeder JS, Sterner S: Glucagon therapy for beta-blocker overdose. Drug Intell Clin Pharm. 1984 May;18(5):394-8. [Article]
  12. Shroff GR, Herzog CA: beta-Blockers in dialysis patients: a nephrocardiology perspective. J Am Soc Nephrol. 2015 Apr;26(4):774-6. doi: 10.1681/ASN.2014080831. Epub 2014 Oct 30. [Article]
  13. Albouaini K, Andron M, Alahmar A, Egred M: Beta-blockers use in patients with chronic obstructive pulmonary disease and concomitant cardiovascular conditions. Int J Chron Obstruct Pulmon Dis. 2007;2(4):535-40. [Article]
  14. Zeng W, Lao S, Guo Y, Wu Y, Huang M, Tomlinson B, Zhong G: The Influence of EGCG on the Pharmacokinetics and Pharmacodynamics of Bisoprolol and a New Method for Simultaneous Determination of EGCG and Bisoprolol in Rat Plasma. Front Nutr. 2022 May 31;9:907986. doi: 10.3389/fnut.2022.907986. eCollection 2022. [Article]
  15. William D. Tucker; Pramod Theetha Kariyanna (2019). Selective B1 blockers. Stat Pearls Publishing.
  16. National Collaborating Centre for Women's and Children's Health (UK) (2010). NICE Guidelines for hypertension in pregnancy. RCOG Press.
  17. Bisoprolol monograph [Link]
  18. Summary of product characteristics [Link]
  19. Bisoprolol, health links AU [Link]
  20. CaymanChem: Bisoprolol MSDS [Link]
  21. Monograph, Bisoprolol [Link]
  22. DailyMed Label: Bisoprolol fumarate Oral Tablets [Link]
  23. Health Canada Approved Drug Products: BISOPROLOL (bisoprolol fumarate) tablets for oral use (January 2020) [Link]
Human Metabolome Database
KEGG Compound
PubChem Compound
PubChem Substance
Therapeutic Targets Database
RxList Drug Page Drug Page
PDRhealth Drug Page

Clinical Trials

Clinical Trials


  • Aurobindo pharma ltd
  • Mutual pharmaceutical co inc
  • Mylan pharmaceuticals inc
  • Sandoz inc
  • Teva pharmaceuticals usa
  • Unichem pharmaceuticals (usa) inc
  • Duramed pharmaceuticals inc sub barr laboratories inc
  • Atlantic Biologicals Corporation
  • Aurobindo Pharma Ltd.
  • Duramed
  • Eon Labs
  • Greenstone LLC
  • Kaiser Foundation Hospital
  • Lake Erie Medical and Surgical Supply
  • Murfreesboro Pharmaceutical Nursing Supply
  • Mylan
  • Novopharm Ltd.
  • Physicians Total Care Inc.
  • Resource Optimization and Innovation LLC
  • Teva Pharmaceutical Industries Ltd.
  • Unichem Laboratories Ltd.
  • Watson Pharmaceuticals
  • Wyeth Pharmaceuticals
Dosage Forms
Tablet, film coatedOral1.25 MG
Tablet, film coatedOral3.75 MG
Tablet, film coatedOral7.5 MG
TabletOral7.5 MG
Tablet, film coatedOral2.5 mg
Tablet, film coatedOral5 mg
TabletOral10 mg/1
TabletOral5 mg/1
Tablet, coatedOral10 mg/1
Tablet, coatedOral5 mg/1
Tablet, film coatedOral10 mg/1
Tablet, film coatedOral5 mg/1
Tablet, coatedOral
Tablet, film coatedOral
Tablet, film coatedOral
Tablet, film coatedOral1.06 MG
Tablet, film coatedOral2.50 MG
TabletOral1.25 MG
TabletOral3.75 MG
TabletOral10.000 mg
TabletOral1.250 mg
Tablet, coatedOral10 mg
TabletOral10 mg
TabletOral5 mg
Tablet, coatedOral1.25 mg
Tablet, coatedOral1000000 mg
Tablet, film coatedOral500000 mg
Tablet, film coatedOral10 mg
Tablet, film coatedOral5 mg
TabletOral5.00 mg
Tablet, film coatedOral10 MG
TabletOral10 mg
TabletOral2.500 mg
TabletOral2.5 mg
TabletOral5 mg
Tablet, coatedOral5 mg
Tablet, coatedOral2.5 mg
Unit descriptionCostUnit
Condylox 0.5% Gel 3.5 gm Tube304.93USD tube
Condylox 0.5% Solution 3.5ml Bottle143.4USD bottle
Condylox 0.5% gel97.73USD g
Zebeta 10 mg tablet3.6USD tablet
Zebeta 5 mg tablet3.6USD tablet
Bisoprolol fumarate 5 mg tablet1.78USD tablet
Bisoprolol fumarate 10 mg tablet1.24USD tablet
Bisoprolol-Hydrochlorothiazide 10-6.25 mg tablet1.19USD tablet
Bisoprolol-Hydrochlorothiazide 2.5-6.25 mg tablet1.19USD tablet
Bisoprolol-Hydrochlorothiazide 5-6.25 mg tablet1.19USD tablet
Apo-Bisoprolol 10 mg Tablet0.38USD tablet
Novo-Bisoprolol 10 mg Tablet0.38USD tablet
Pms-Bisoprolol 10 mg Tablet0.38USD tablet
Sandoz Bisoprolol 10 mg Tablet0.38USD tablet
Apo-Bisoprolol 5 mg Tablet0.23USD tablet
Novo-Bisoprolol 5 mg Tablet0.23USD tablet
Pms-Bisoprolol 5 mg Tablet0.23USD tablet
Sandoz Bisoprolol 5 mg Tablet0.23USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Not Available


Experimental Properties
melting point (°C)100-103
boiling point (°C)445.0±45.0
Predicted Properties
Water Solubility0.0707 mg/mLALOGPS
pKa (Strongest Acidic)14.09Chemaxon
pKa (Strongest Basic)9.67Chemaxon
Physiological Charge1Chemaxon
Hydrogen Acceptor Count5Chemaxon
Hydrogen Donor Count2Chemaxon
Polar Surface Area59.95 Å2Chemaxon
Rotatable Bond Count12Chemaxon
Refractivity92.15 m3·mol-1Chemaxon
Polarizability38.5 Å3Chemaxon
Number of Rings1Chemaxon
Rule of FiveYesChemaxon
Ghose FilterYesChemaxon
Veber's RuleNoChemaxon
MDDR-like RuleNoChemaxon
Predicted ADMET Features
Human Intestinal Absorption+0.9445
Blood Brain Barrier-0.9077
Caco-2 permeable+0.6149
P-glycoprotein substrateSubstrate0.7785
P-glycoprotein inhibitor INon-inhibitor0.807
P-glycoprotein inhibitor IINon-inhibitor0.7821
Renal organic cation transporterNon-inhibitor0.8568
CYP450 2C9 substrateNon-substrate0.8134
CYP450 2D6 substrateSubstrate0.8919
CYP450 3A4 substrateNon-substrate0.6113
CYP450 1A2 substrateNon-inhibitor0.9046
CYP450 2C9 inhibitorNon-inhibitor0.9071
CYP450 2D6 inhibitorNon-inhibitor0.923
CYP450 2C19 inhibitorNon-inhibitor0.9485
CYP450 3A4 inhibitorNon-inhibitor0.8373
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9766
Ames testNon AMES toxic0.9064
BiodegradationNot ready biodegradable0.8962
Rat acute toxicity2.0089 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.7877
hERG inhibition (predictor II)Non-inhibitor0.6611
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)


Mass Spec (NIST)
Not Available
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSsplash10-05g0-9851000000-9065ddf0b986c238395e
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-004i-0109000000-564ffde4ea3f59c4126f
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-014i-2903000000-5e5b905ef2026aa7f011
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-00xr-9800000000-99ce6ca7b3171d63af09
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-00di-9600000000-bfefc02f00a4439a34ba
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-05fr-9500000000-4b91d206ced038eff35c
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0ab9-9400000000-dd6baeb57f900d719aa9
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-004i-0209000000-0f37dcfed3fc1c82c470
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-014i-5902000000-dae2a435db6b3ea664cd
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-05fr-9200000000-1cce569461a677bb6467
MS/MS Spectrum - , positiveLC-MS/MSsplash10-004i-0209000000-65dd49cd88f0ec134445
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-00or-5709000000-360e67ed724045a9c01b
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSsplash10-00di-1392000000-383aa58e1e42527642c5
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSsplash10-0ir1-1960000000-06850a1e570583b89de4
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSsplash10-014i-5290000000-cedb9b055fb912039e4a
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSsplash10-00dl-6900000000-f7b17632ff5b94375c83
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSsplash10-052f-9200000000-2f28d2c3a5b860a640c2
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSsplash10-05fr-4900000000-3fa53ffaead313045f2c
Predicted 1H NMR Spectrum1D NMRNot Applicable
Predicted 13C NMR Spectrum1D NMRNot Applicable
Chromatographic Properties
Collision Cross Sections (CCS)
AdductCCS Value (Å2)Source typeSource
DarkChem Lite v0.1.0
DeepCCS 1.0 (2019)
DarkChem Lite v0.1.0
DeepCCS 1.0 (2019)
DarkChem Lite v0.1.0
DeepCCS 1.0 (2019)


Build, predict & validate machine-learning models
Use our structured and evidence-based datasets to unlock new
insights and accelerate drug research.
Learn more
Use our structured and evidence-based datasets to unlock new insights and accelerate drug research.
Learn more
Pharmacological action
General Function
Receptor signaling protein activity
Specific Function
Beta-adrenergic receptors mediate the catecholamine-induced activation of adenylate cyclase through the action of G proteins. This receptor binds epinephrine and norepinephrine with approximately e...
Gene Name
Uniprot ID
Uniprot Name
Beta-1 adrenergic receptor
Molecular Weight
51322.1 Da
  1. Breed JG, Ciampricotti R, Tromp GP, Valster FA, Lageweg E, Van Bortel LM: Quality of life perception during antihypertensive treatment: a comparative study of bisoprolol and enalapril. J Cardiovasc Pharmacol. 1992;20(5):750-5. [Article]
  2. Brouri F, Hanoun N, Mediani O, Saurini F, Hamon M, Vanhoutte PM, Lechat P: Blockade of beta 1- and desensitization of beta 2-adrenoceptors reduce isoprenaline-induced cardiac fibrosis. Eur J Pharmacol. 2004 Feb 6;485(1-3):227-34. [Article]
  3. Bruck H, Leineweber K, Temme T, Weber M, Heusch G, Philipp T, Brodde OE: The Arg389Gly beta1-adrenoceptor polymorphism and catecholamine effects on plasma-renin activity. J Am Coll Cardiol. 2005 Dec 6;46(11):2111-5. Epub 2005 Nov 4. [Article]
  4. Lipworth BJ, Irvine NA, McDevitt DG: A dose-ranging study to evaluate the beta 1-adrenoceptor selectivity of bisoprolol. Eur J Clin Pharmacol. 1991;40(2):135-9. [Article]
  5. Mauz AB, Pelzer H: Beta-adrenoceptor-binding studies of the cardioselective beta blockers bisoprolol, H-I 42 BS, and HX-CH 44 BS to heart membranes and intact ventricular myocytes of adult rats: two beta 1-binding sites for bisoprolol. J Cardiovasc Pharmacol. 1990 Mar;15(3):421-7. [Article]
  6. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [Article]
Pharmacological action
Curator comments
At higher doses, bisoprolol antagonizes the B2 receptors, but is normally selective for B1 receptors.
General Function
Protein homodimerization activity
Specific Function
Beta-adrenergic receptors mediate the catecholamine-induced activation of adenylate cyclase through the action of G proteins. The beta-2-adrenergic receptor binds epinephrine with an approximately ...
Gene Name
Uniprot ID
Uniprot Name
Beta-2 adrenergic receptor
Molecular Weight
46458.32 Da
  1. Mark G. Papich (2016). Saunders Handbook of Veterinary Drugs (4th ed.). Saunders.
  2. Summary of product characteristics [Link]


Pharmacological action
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
Uniprot ID
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
  1. Horikiri Y, Suzuki T, Mizobe M: Pharmacokinetics and metabolism of bisoprolol enantiomers in humans. J Pharm Sci. 1998 Mar;87(3):289-94. [Article]
  2. Zisaki A, Miskovic L, Hatzimanikatis V: Antihypertensive drugs metabolism: an update to pharmacokinetic profiles and computational approaches. Curr Pharm Des. 2015;21(6):806-22. [Article]
  3. Bisoprolol monograph [Link]


Pharmacological action
General Function
Xenobiotic-transporting atpase activity
Specific Function
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name
Uniprot ID
Uniprot Name
Multidrug resistance protein 1
Molecular Weight
141477.255 Da
  1. Bachmakov I, Werner U, Endress B, Auge D, Fromm MF: Characterization of beta-adrenoceptor antagonists as substrates and inhibitors of the drug transporter P-glycoprotein. Fundam Clin Pharmacol. 2006 Jun;20(3):273-82. doi: 10.1111/j.1472-8206.2006.00408.x. [Article]
  2. Tahara K, Kagawa Y, Takaai M, Taguchi M, Hashimoto Y: Directional transcellular transport of bisoprolol in P-glycoprotein-expressed LLC-GA5-COL150 cells, but not in renal epithelial LLC-PK1 Cells. Drug Metab Pharmacokinet. 2008;23(5):340-6. [Article]
  3. Nehaj F, Sokol J, Ivankova J, Mokan M, Mokan M: Effect of Bisoprolol on the Level of Dabigatran. Am J Ther. 2018 Jul 12. doi: 10.1097/MJT.0000000000000786. [Article]
  4. Klatt S, Fromm MF, Konig J: Transporter-mediated drug-drug interactions with oral antidiabetic drugs. Pharmaceutics. 2011 Oct 12;3(4):680-705. doi: 10.3390/pharmaceutics3040680. [Article]

Drug created at June 13, 2005 13:24 / Updated at May 29, 2024 19:09